If I Have Herpes, Will My Partner Catch It?

Transmission is possible but far from guaranteed, and several choices you and your partner make together can push the odds substantially lower. In a large clinical trial, when the infected partner took no antiviral medication and the couple did not consistently use condoms, the annual transmission rate from an HSV-2-positive person to a susceptible partner was roughly 4 percent. That number drops further with daily suppressive therapy, barrier protection, and avoiding sex during outbreaks. Understanding what drives that risk, and where the common fears overstate it, is worth the time.

What the Baseline Numbers Actually Look Like

The clearest data on partner-to-partner transmission comes from a randomized trial of more than 1,400 couples where one partner had genital HSV-2 and the other did not. In the placebo arm, where infected partners took no antiviral medication, about 3.6 percent of susceptible partners acquired HSV-2 over eight months of follow-up.¹ That works out to roughly a 4 to 5 percent annual risk without any specific precautions beyond the couple’s own behavior.

Gender matters. An earlier prospective study found that women who had no prior antibodies to either herpes type had an annual acquisition rate of about 32 percent when their male partner was infected, while women who already carried HSV-1 antibodies had a rate closer to 9 percent.² Transmission from women to men runs lower in most studies, likely because of anatomical differences in mucosal exposure. So your partner’s sex and prior HSV-1 status both shift the math.

Why Herpes Spreads Even Without Symptoms

One of the trickiest things about herpes is that the virus sheds from the skin even when no sores are visible. A study tracking daily genital swabs found that HSV-2 was detectable on about 12 percent of days when no lesions were reported. Among people who had symptomatic outbreaks, subclinical shedding occurred on roughly 13 percent of asymptomatic days; among people who had never noticed symptoms, shedding still happened on about 9 percent of days.³

This means the virus doesn’t announce itself every time it reaches the skin’s surface. Modeling work suggests that most sexual transmissions actually happen during these silent shedding episodes, when viral loads are high enough to infect but the sore is either too small to see or absent entirely.⁴ That finding is counterintuitive for many people, who assume the danger is only during visible outbreaks. Outbreaks are certainly riskier per encounter, but they account for a minority of total infectious days over the course of a year.

How Antivirals Cut the Risk

Daily suppressive therapy with valacyclovir (the most commonly studied drug for this purpose) reduced transmission by about half in the large trial mentioned earlier. Among couples assigned to the antiviral arm, only 1.9 percent of susceptible partners acquired HSV-2, compared with 3.6 percent in the placebo group.¹ That roughly 50 percent relative reduction is the number most clinicians reference when counseling discordant couples.

One important caveat: this protection applies best when the infected partner is otherwise healthy. A trial in couples where the HSV-2-positive partner also had HIV found that daily acyclovir did not significantly reduce HSV-2 transmission to the uninfected partner.⁵ HIV impairs immune surveillance of HSV, so the co-infected setting is biologically different. For people without HIV, the evidence for suppressive antivirals remains strong.

Suppressive therapy also reduces the frequency and severity of outbreaks, which has an indirect benefit: fewer symptomatic episodes means fewer days when transmission risk is at its peak. For many couples, the combination of lower shedding rates and fewer visible outbreaks provides meaningful peace of mind.⁶

What Condoms Add

Condoms are imperfect for herpes prevention because the virus can shed from skin not covered by a condom, including the thighs, buttocks, and perianal area. Still, they help. A pooled analysis of six studies found that people who used condoms every time had about a 30 percent lower risk of acquiring HSV-2 compared with those who never used them.⁷ That 30 percent figure reflects the imperfect coverage, but it compounds on top of other strategies.

Per-act data tells a more nuanced story. One analysis of HIV/HSV-2-discordant couples found condom use reduced the per-act risk of male-to-female transmission by about 96 percent and female-to-male transmission by about 65 percent, though the latter didn’t quite reach statistical significance.⁸ The directional difference again reflects anatomy: the virus in men tends to shed from the penile shaft, which a condom covers well, while in women shedding occurs over a broader area.

When you stack the strategies, the combined risk drops further. A couple using daily suppressive antivirals and consistent condoms, while also avoiding sex during outbreaks, is looking at a meaningfully lower annual transmission risk than the raw 4 to 5 percent baseline. Some clinicians estimate the combined annual risk falls below 1 to 2 percent, though that number is extrapolated rather than tested in a single trial combining all three interventions simultaneously.

Prodromal Signs and When to Pause

Many people with herpes notice tingling, itching, or a burning sensation in the affected area a day or two before a visible sore appears. These prodromal symptoms signal that the virus is actively replicating near the skin surface, and viral loads during this window can be high enough to transmit. Avoiding sexual contact from the first hint of prodrome through complete healing of any sore is standard guidance.

The research on viral load and transmission probability supports this approach. Transmission becomes unlikely at low viral loads, but prolonged episodes with high copy numbers, including ones where the resulting ulcer is too small to be noticed, account for most transmissions.⁴ If you know your body’s prodromal signals, you can catch many of these higher-risk windows. The tricky ones are the sub-clinical episodes where neither you nor your partner would notice anything.

HSV-1 Genital Infections Shed Less

A growing number of genital herpes cases are caused by HSV-1 rather than HSV-2, often acquired through oral sex. This matters for transmission because genital HSV-1 is considerably less active than genital HSV-2. In the first year after a first clinical episode, genital HSV-2 sheds on about a third of days, and even a decade later it is still detectable on roughly 17 percent of days. Genital HSV-1 shedding rates are lower than both of those benchmarks.⁹

The clinical implication is that if you carry genital HSV-1, the risk of transmitting it genitally to a partner is lower than if you had HSV-2. Recurrences are also less frequent. That said, genital HSV-1 is still transmissible, and your partner could acquire it as a genital or oral infection depending on the type of contact.

How Oral HSV-1 Can Lead to Genital Infections

Most genital HSV-1 infections appear to be acquired from a partner’s oral secretions during oral sex rather than from genital-to-genital contact. HSV-1 sheds frequently from the oral cavity, and this frequent oral shedding is a public health concern because it can lead to genital infections in the receiving partner.¹⁰ If you carry oral HSV-1, performing oral sex on a partner who doesn’t have HSV-1 can pass the virus to their genital area, potentially causing a first episode of genital herpes. Dental dams or condoms during oral sex reduce this risk, though they are underused in practice.

Does Your Partner’s Existing HSV-1 Offer Any Protection?

If your partner already carries HSV-1, they have some degree of cross-reactive immune response against HSV-2. The two virus types share enough genetic similarity that antibodies to one can partially interfere with the other. As noted earlier, women with pre-existing HSV-1 antibodies had an annual acquisition rate of about 9 percent from an infected male partner, versus roughly 32 percent for women with no prior HSV antibodies of either type.²

Animal research confirms the principle: mice infected orally with HSV-1 and then challenged vaginally with HSV-2 were partially protected from acquiring the second virus, and when they did acquire it, the resulting genital infection was milder and far less lethal.¹¹ This doesn’t make your partner immune, but it does lower the probability and severity of transmission.

Male Circumcision and HSV-2 Risk

Circumcision reduces the risk of a man acquiring HSV-2. In a randomized trial in Uganda, the cumulative probability of HSV-2 infection at 24 months was about 8 percent in circumcised men versus about 10 percent in uncircumcised men, a relative risk reduction of roughly 28 percent.¹² A review across studies puts the protective effect at around 30 percent for men.¹³

The protection does not extend to female partners of circumcised men, however. A randomized trial assessing HSV-2 acquisition among the female partners of men randomized to circumcision or no circumcision found no difference.¹⁴ So if the infected partner is male, his circumcision status does not appear to help protect his female partner from HSV-2.

Can You Catch Herpes From Toilet Seats or Shared Objects?

This is one of the most persistent fears, and the short answer is that real-world transmission from surfaces is extremely unlikely. Lab studies have shown that herpes simplex virus can survive on plastic surfaces in humid, warm conditions for up to about four and a half hours.¹⁵ On toothbrushes and similar personal items, the quantity of replication-capable virus drops significantly within two hours of contamination and approaches zero by 24 hours.¹⁶

Survival on a surface, though, is not the same as transmission. The virus needs to reach a mucous membrane or broken skin in sufficient quantity. Casual contact with a dry toilet seat or a shared towel just isn’t an efficient route. The overwhelming majority of herpes transmission happens through direct skin-to-skin or mucosal contact during sexual activity or kissing.

Stress and Outbreaks

You may have heard that stress triggers herpes outbreaks, and there is evidence for a connection, at least on the outbreak side. A study of HSV-2-positive women found that high stress levels in the five days before an outbreak were associated with three times the rate of lesion onset compared with low stress levels. High anxiety was linked to five or more times the rate, and high depression scores were linked to six or more times the rate of lesion onset.¹⁷

An important distinction emerged from the same study: while stress predicted visible outbreaks, it was not associated with the rate of viral shedding itself.¹⁷ That means stress may make you more likely to have a noticeable outbreak, giving you a clear signal to avoid contact, but it doesn’t seem to increase the silent shedding that drives most transmissions. Stress management is still worthwhile for your own comfort and quality of life, but it shouldn’t be thought of as a transmission-reduction strategy in the same category as antivirals or condoms.

Pregnancy and Protecting a Newborn

If you or your partner are thinking about pregnancy, the timing of a herpes infection relative to delivery is the critical variable. Women who acquire a new genital herpes infection during pregnancy face a much greater risk of passing the virus to the baby than women who had recurrent herpes before becoming pregnant.¹⁸ A first episode in the third trimester is the most dangerous scenario. In one early study, four out of five infants born to mothers who acquired primary HSV-2 in the third trimester had perinatal complications including prematurity and neonatal herpes infection.¹⁹

The reason is immunological. When a woman acquires herpes for the first time late in pregnancy, she hasn’t yet built up the antibodies that would otherwise cross the placenta and offer the baby partial protection. Among women shedding virus at delivery, the absence of type-specific maternal antibodies was linked to dramatically higher transmission rates to the infant.²⁰ By contrast, a woman with long-standing herpes has circulating antibodies that cross to the baby and substantially lower the neonatal risk. Cesarean delivery when active lesions are present at the time of labor is a standard precaution, and suppressive antiviral therapy is typically prescribed from 36 weeks onward for women with a history of genital herpes.

Telling Your Partner

The emotional weight of disclosure is real and widely studied. In a survey of people attending a herpes clinic, stigma was a significant barrier to telling sexual partners about a diagnosis. Disclosure tended to happen more readily in established relationships than in new ones, and about a third of participants reported moderate to severe anxiety related to their herpes status.²¹ Common emotional responses after diagnosis include fear of telling partners, concern about being seen as sexually undesirable, and feeling socially stigmatized.²²

None of this makes disclosure optional from an ethical standpoint, but understanding the psychological dynamics helps explain why people delay it and why destigmatizing herpes is a public health priority, not just a feel-good message. Knowing the actual transmission numbers, rather than the inflated fear-based versions most people carry around, can make the conversation easier. When you can tell a partner “the annual risk with antivirals and condoms is likely under 2 percent” rather than vaguely saying “there’s a chance,” the conversation lands differently.

Testing Pitfalls Worth Knowing

Blood tests for herpes antibodies have limits that can cause confusion. In the early stage of infection, antibodies may not yet be detectable, leading to false negative results.²³ It can take several weeks to a few months after infection for antibody levels to rise high enough to register on a test. So a negative blood test right after exposure doesn’t rule anything out. Direct testing of a lesion by PCR is more accurate during an active outbreak and can distinguish between HSV-1 and HSV-2, which matters for predicting future shedding and recurrence patterns.

Where Vaccine Research Stands

There is no approved vaccine for herpes simplex as of now, despite decades of effort. Both preventive vaccines (aimed at keeping uninfected people from acquiring the virus) and therapeutic vaccines (aimed at reducing outbreaks and shedding in people who already carry it) remain in various stages of research.²⁴ Several candidates have made it to clinical trials only to fall short of efficacy endpoints, a track record that reflects how effectively HSV evades the immune system.²⁵ The virus establishes a lifelong latent infection in nerve ganglia that is largely invisible to immune surveillance, making a sterilizing vaccine an unusually tough goal. Newer approaches using mRNA platforms and gene-editing tools are in early development, but none is close to market. For now, the practical toolkit remains antivirals, condoms, outbreak awareness, and honest communication.